MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.02
+0.27
+2.12%
Closed 17:20 08/12 EDT
OPEN
12.71
PREV CLOSE
12.75
HIGH
13.26
LOW
12.71
VOLUME
344.08K
TURNOVER
--
52 WEEK HIGH
17.20
52 WEEK LOW
3.500
MARKET CAP
410.49M
P/E (TTM)
-11.5272
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BCLI stock price target is 22.33 with a high estimate of 33.00 and a low estimate of 14.00.

EPS

BCLI News

More
BCLI: Phase 3 ALS Data Expected by the End of November 2020…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in p
Zacks Small Cap Research · 5d ago
Brainstorm Cell Q2 EPS $(0.25) Beats $(0.26) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 8.7 percent decrease over losses of $(0.23) per share from the
Benzinga · 08/05 11:19
Brainstorm Cell Q2 EPS $(0.25) Beats $(0.26) Estimate
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 8.7 percent decrease over losses of $(0.23) per share from the
Benzinga · 08/05 11:19
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update.
PR Newswire · 08/05 11:00
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financi
PR Newswire · 07/27 11:58
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
  Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23)
Benzinga · 07/24 11:15
5 Stock Gainers for Thursday: Smith & Wesson, Calix, Sunopta
Smith & Wesson Brands, Calix, Sunopta, eXp Realty, and Vivent Solar are some of Thursday's movers.
TheStreet.com · 07/23 20:36
BrainStorm's NurOwn shows encouraging action in lung inflammation model
BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces encouraging results from a preclinical study assessing NurOwn (MSC-NTF cells) in a mouse model of lipo
seekingalpha · 07/23 17:00

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About BCLI

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.